HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial

BACKGROUND: HER2DX is a prognostic and predictive assay in early-stage HER2-positive breast cancer based on clinical features and the expression of 4 gene signatures (immune, proliferation, luminal differentiation and HER2 amplicon), including ERBB2 mRNA levels. Here, we evaluated the ability of HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Guarneri, Valentina, Brasó-Maristany, Fara, Dieci, Maria Vittoria, Griguolo, Gaia, Paré, Laia, Marín-Aguilera, Mercedes, Miglietta, Federica, Bottosso, Michele, Giorgi, Carlo Alberto, Blasco, Paula, Castillo, Oleguer, Galván, Patricia, Vivancos, Ana, Villagrasa, Patricia, Parker, Joel S., Perou, Charles M., Conte, PierFranco, Prat, Aleix
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626543/
https://www.ncbi.nlm.nih.gov/pubmed/36374768
http://dx.doi.org/10.1016/j.ebiom.2022.104320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9626543/
https://www.ncbi.nlm.nih.gov/pubmed/36374768
http://dx.doi.org/10.1016/j.ebiom.2022.104320

Ejemplares similares